Stockscreener 앱 받기
4.21
5.52%
-0.23
Cingulate Inc 주식(CING)의 최신 뉴스
Shane Schaffer reinstated as CEO of Cingulate - marketscreener.com
Cingulate reinstates Shane Schaffer as CEO, updates employment terms - Investing.com India
Cingulate Inc Reinstates Shane Schaffer as CEO - TipRanks
Cingulate Inc Equity Warrant Stock Analysis and ForecastEarnings Season Recap & Outstanding Capital Returns - earlytimes.in
Cingulate presents Phase 3 results for CTx-1301, met primary endpoint - MSN
Ascendiant Capital Maintains Cingulate (CING) Buy Recommendation - Nasdaq
Cingulate reports Q3 net loss ($7.3M) vs ($4.1M) last year - MSN
Cingulate Inc. Reports Q3 2025 Financial Results - MSN
Can Cingulate Inc. Equity Warrant stock deliver surprise earnings beatMarket Growth Report & Stepwise Trade Signal Implementation - Newser
Will Cingulate Inc. stock attract more institutional investorsPortfolio Gains Summary & Fast Exit Strategy with Risk Control - Newser
How strong is Cingulate Inc. stock balance sheetCEO Change & Accurate Intraday Trade Tips - Newser
Cingulate Inc. (NASDAQ:CING) Given Average Recommendation of “Moderate Buy” by Brokerages - Defense World
How Dhanvantri Jeevan Rekha Limiteds Balance Sheet Supports LongTerm GrowthPrice Support Zones & Superior Wealth Building - earlytimes.in
Cingulate Inc Stock Analysis and ForecastEnergy Sector Updates & Chat With Other Investors on Daily Signals - earlytimes.in
Will Cingulate Inc. stock maintain dividend yieldEarnings Recap Summary & Precise Buy Zone Tips - moha.gov.vn
Will Cingulate Inc. stock return to pre crisis levelsPortfolio Return Summary & Consistent Growth Equity Picks - BỘ NỘI VỤ
Sentiment Recap: Will Cingulate Inc. stock gain from lower inflation2025 Major Catalysts & High Accuracy Swing Entry Alerts - moha.gov.vn
Who’s Hired? Alvotech Promotes McClellan To COO - Citeline News & Insights
Is There NearTerm Timing Risk on India Glycols Limited StockPrice Momentum Alerts & Big Gains Low Investment - earlytimes.in
Press Release: Cingulate Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update - 富途牛牛
Is Cingulate Inc. Equity Warrant stock dividend yield sustainable - newser.com
Zacks Small Cap Lowers Earnings Estimates for Cingulate - Defense World
Cingulate price target lowered to $16 from $17 at Roth Capital - Yahoo Finance
Why Cingulate Inc. Equity Warrant stock remains on buy listsPortfolio Return Report & Safe Entry Zone Identification - newser.com
Will breakout in Cingulate Inc. Equity Warrant lead to full recoveryJuly 2025 Trends & Technical Analysis for Trade Confirmation - newser.com
What data driven models say about Cingulate Inc.’s futureMarket Sentiment Report & Short-Term High Return Strategies - newser.com
How Cingulate Inc. stock performs in high volatility markets2025 EndofYear Setup & Safe Entry Zone Tips - newser.com
Signal strength of Cingulate Inc. stock in tech scannersWeekly Trend Recap & Real-Time Stock Entry Alerts - newser.com
Will Cingulate Inc. Equity Warrant stock recover faster than marketJuly 2025 Patterns & Capital Efficiency Focused Ideas - newser.com
Published on: 2025-11-19 18:10:29 - newser.com
Can Cingulate Inc. Equity Warrant stock deliver consistent earnings growth - newser.com
Strategies to average down on Cingulate Inc. Equity Warrant2025 Fundamental Recap & Safe Swing Trade Setup Alerts - newser.com
Is Cingulate Inc. Equity Warrant stock in correction or buying zoneJuly 2025 Levels & AI Based Buy and Sell Signals - newser.com
Roth Capital Maintains Cingulate (CING) Buy Recommendation - Nasdaq
Is Cingulate Inc. stock ready for a breakoutJuly 2025 Recap & Community Verified Trade Signals - newser.com
Published on: 2025-11-19 05:53:07 - newser.com
Can Cingulate Inc. stock sustain revenue growthTrade Entry Report & Safe Entry Trade Signal Reports - newser.com
Cingulate Advances ADHD Treatment CTx-1301 Toward Potential 2026 FDA Approval - citybuzz
Does Cingulate Inc. fit your quant trading modelQuarterly Portfolio Report & Target Return Focused Picks - newser.com
Stonegate Capital Partners Updates Coverage on Cingulate Inc. (CING) 3Q25 - TradingView
Cingulate (NASDAQ: CING) Gains FDA Acceptance of CTx-1301 NDA, Eyes ADHD Launch - Stock Titan
0.56%
1.23%
자본화:
|
볼륨(24시간):